Faculty of Infectious and Tropical Diseases, London School of Hygiene & Tropical Medicine, London, UK.
Clin Microbiol Infect. 2011 Oct;17(10):1478-83. doi: 10.1111/j.1469-0691.2011.03630.x.
Although there have been significant advances in the treatment of visceral leishmaniasis (VL), there remain challenges to ensure that treatments effective in India are also effective in other regions of the world and to identify treatment for post kala-azar dermal leishmaniasis as well as the opportunity to develop a safe oral short-course treatment. At the same time, there have been few advances for the treatment of simple or complex forms of cutaneous leishmaniasis (CL), other than topical paromomycin formulations. The main challenge for CL is to ensure that this disease is on the research and development agenda, so that new drugs are evaluated or compounds are screened in appropriate models, and that the standardization of quality of clinical trials is guaranteed. Problems also remain in the treatment of HIV/leishmaniasis co-infected patients. We are some way from having the ideal treatments for VL and CL and drug research and development for these diseases must remain focused.
尽管内脏利什曼病（VL）的治疗已经取得了重大进展，但仍存在一些挑战，需要确保在印度有效的治疗方法在世界其他地区也同样有效，并找到治疗黑热病后皮肤利什曼病的方法，以及开发安全的口服短期疗程治疗方法的机会。与此同时，除了局部使用帕莫霉素制剂外，针对简单或复杂形式的皮肤利什曼病（CL）的治疗方法几乎没有进展。CL 的主要挑战是确保该疾病列入研究和开发议程，以便在适当的模型中评估新药或筛选化合物，并保证临床试验质量的标准化。HIV/利什曼病合并感染患者的治疗也存在问题。我们距离拥有 VL 和 CL 的理想治疗方法还有一段距离，因此这些疾病的药物研究和开发必须保持重点关注。
